

Changes to Board of NeuroScientific

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) ("**NeuroScientific**") announces that as a result of the change in strategy of the company's R&D pathway, two new directors have joined the Board to assist with a strategic review of the company's assets and future direction. Mr Clarke Barlow and Mr Chris Ntoumenopoulos will both join the Board, effective Friday 17 November 2023.

Mr Chris Ntoumenopoulos is the Managing Director of Twenty 1 Corporate, an Australian advisory firm. With over 20 years in financial markets, he has a strong background in raising capital and offering corporate advisory services. His experience also extends to directorial roles, having served on the boards of ASX listed companies for over 7 years. Chris was a foundational director of ResApp Health Ltd (RAP.ASX), later acquired by Pfizer, and Race Oncology (RAC.ASX). Presently, Chris is a non-executive director at Medibio (MEB.ASX).

Mr Clarke Barlow is a Financial Adviser with 22 years' experience in the Financial Services Industry in Australia and the United Kingdom (UK). Since 2007, Clarke has provided corporate advisory services for ASX listed companies across a variety of industries, with a focus on growth opportunities, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, M&A, investor relations and capital markets advice. Mr Barlow currently serves as a Non-Executive Director of ASX listed biotechnology company Exopharm Limited (ASX : EX1) and is a Founder and Director of AMG Acquisition Corp, a publicly listed company on the Toronto Venture Exchange. He holds a Bachelor of Commerce degree from the University of Western Australia, has level 2 ASX derivatives accreditation, and is a member of the Australian Institute of Company Directors (AICD).

As a result of this change in strategy and direction, Dr Linda Friedland has chosen not to stand for election at the upcoming Annual General Meeting, and therefore steps down from the Board, effective Friday 17 November 2023.

In accordance with the Company's Constitution, Mr Clarke Barlow and Mr Chris Ntoumenopoulos will stand for election at the Company's Annual General Meeting in November 2023, and the Company will shortly release an addendum to the Notice of Meeting to this effect.

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS

For more information please contact:

Paul Rennie
Non-executive Chair
ir@neuroscientific.com
+ 61 8 6382 1805

Abby Macnish Niven
CFO and Company Secretary
ir@neuroscientific.com
+ 61 8 6382 1805

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.